Can Olive Oil Polyphenols Lower LDL Particle Burden Better Than Refined Oil?
Most people hear “olive oil is good for your heart” and stop there. That is the nutritional equivalent of saying a car is fast because it has an engine. The real question is what, exactly, changes inside the bloodstream when the oil is rich in polyphenols instead of stripped down by processing. This randomized crossover trial gives a cleaner answer than usual: high-polyphenol olive oil did not just nudge cholesterol numbers, it reduced apoB-100, total LDL particles, and small LDL particles in healthy men, while the low-polyphenol comparator did the opposite. That matters because apoB and particle number are closer to the actual disease biology of atherosclerosis than a single LDL-C number ever was.
Study Overview
This is a good design for a nutrition study because the oils were held constant in everything except phenolic content. That removes a lot of the usual noise. The investigators also checked adherence with urinary tyrosol and hydroxytyrosol, which is exactly what you want when the question is about bioactive compounds rather than calories alone.
Key Findings: The Numbers That Matter
The core result is not that olive oil “changed lipids” in a vague sense. It specifically reduced the circulating burden of apoB-containing particles. ApoB-100 fell by 5.94% ± 16.6% after the high-polyphenol oil, while the low-polyphenol oil produced a 6.39% ± 16.6% increase. Total LDL particles dropped 11.9% ± 12.0% with the phenolic-rich oil and rose 4.73% ± 22.0% with the low-phenol comparator. Small LDL particles, the more troublesome subclass, dropped 15.3% ± 35.1% versus a 13.6% ± 36.4% increase in the comparison arm. Those are not cosmetic differences. They point to a real shift in the atherogenic particle pool.
Oxidative biology moved in the same direction. LDL oxidation lag time increased by 5.0% ± 10.3% after the high-polyphenol intervention, and urinary tyrosol and hydroxytyrosol rose sharply, confirming that the participants were actually getting the phenols. The interesting part is the correlation data: larger drops in small LDL particles tracked with higher urinary tyrosol excretion (r = -0.53, P = 0.042) and with improved oxidative status, as measured by the reduced-to-oxidized ascorbic acid ratio (r = -0.66, P = 0.005). That is the sort of dose-response pattern that makes a mechanistic story feel real.
Mechanism: Why Would Phenolic Olive Oil Beat Refined Oil?
1. Less oxidation means less atherogenic remodeling
Polyphenols such as hydroxytyrosol and tyrosol can slow oxidative modification of lipids and lipoproteins. If LDL is less oxidized, it is less likely to become the kind of particle that the artery wall aggressively traps and inflames. The longer oxidation lag time in this trial fits that model.
2. ApoB particle burden may fall through altered clearance
The trend toward higher lipoprotein lipase expression suggests a possible route for faster clearance of triglyceride-rich particles upstream, which would ultimately reduce the pool of small LDL particles downstream. The gene-expression finding did not meet conventional significance, but the direction is biologically plausible and lines up with the lipid changes.
3. Polyphenol density, not just olive oil as a fat, is the differentiator
Both oils were olive oil, so the fatty-acid backbone was similar. That means the phenotype shift is almost certainly about the phenolic fraction and the biological cargo that comes with it. This is exactly why extra-virgin olive oil behaves differently from refined oil in so many cardiovascular studies.
Context: How Does This Fit Previous Research?
This trial does not come out of nowhere. It builds directly on EUROLIVE, which already showed that polyphenol-rich olive oils improve oxidative biomarkers. What Hernáez and colleagues added was more clinically interpretable lipid biology: apoB-100, LDL particle number, and small LDL particles. That is a step forward because LDL-C can stay deceptively “normal” while particle number remains high.
It also makes sense of the broader olive-oil literature. Later RCTs and cohort work have repeatedly suggested that high-phenolic EVOO is the version that matters most for cardiovascular benefit, not just total monounsaturated fat intake. In that sense, this paper is a bridge between the old “Mediterranean diet is good” story and the newer “the phenolic fraction is the useful part” story.
The caveat is that this is still a surrogate-endpoint study in healthy men. It tells us the biology is moving in the right direction, but it does not tell us whether an actual event rate would fall over years. That distinction matters, and too many nutrition headlines pretend it does not.
Practical Takeaway
- • If you are choosing between refined olive oil and extra-virgin olive oil, the phenolic-rich version is the better bet for cardiovascular biology.
- • Think in terms of replacement, not addition. The study swapped 25 mL/day into the diet, not an oil shot on top of everything else.
- • ApoB and LDL particle number are worth paying attention to, especially if LDL-C looks fine but risk remains elevated.
- • This is supportive evidence, not permission to ignore statins, fiber, exercise, or actual lipid management when needed.
Limitations
Small sample
Twenty-five men is enough for a mechanistic trial, not enough for certainty in the wild.
Healthy, male-only population
We should not assume the same magnitude in women, older adults, or people with diabetes or established CVD.
Short intervention
Three weeks shows direction, not durability.
Surrogate outcomes
LDL particles and oxidation are important, but they are still not hard cardiovascular events.
Our Take
This is not a flashy trial, but it is a good one. It isolates the phenolic fraction, uses a crossover design, checks adherence with urinary metabolites, and measures particle-level lipid biology rather than relying only on LDL-C. That makes it much more convincing than the usual olive-oil wellness material.
My read is that the study is strong mechanistically and modest clinically. It does not prove that high-phenolic olive oil prevents heart attacks by itself, but it does show a plausible path from bottle quality to lower atherogenic burden. If you care about heart health, that is enough to make extra-virgin the default choice.
In other words, this paper does not just say olive oil is healthy. It explains why the best olive oil is healthier.
References
1. Hernáez Á, Remaley AT, Farràs M, et al. Olive Oil Polyphenols Decrease LDL Concentrations and LDL Atherogenicity in Men in a Randomized Controlled Trial. J Nutr. 2015;145(8):1692-1697. doi:10.3945/jn.115.211557. PMID: 26136585. PubMed →
2. Full text: PMC4516770 →
Bottom line
High-polyphenol olive oil lowered apoB, total LDL particles, and small LDL particles more than low-polyphenol oil, which is exactly the sort of result that makes EVOO worth caring about.
See all research →